Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial
Nogueira MA, Oliveira CP, Ferreira Alves VA, Stefano JT, Rodrigues LS, Torrinhas RS, Cogliati B, Barbeiro H, Carrilho FJ, Waitzberg DL
Clinical nutrition (Edinburgh, Scotland) · 98 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2015-05-21 · Clin Nutr · vol. 35 · número 3 · págs. 578–586
- Editorial
- Elsevier BV
- Citado
- 122 citas · más que el 99% de estudios similares · 10.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 36 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Liver Disease Diagnosis and Treatment · Alcohol Consumption and Health Effects
- Palabras clave
- omega-3 polyunsaturated fatty acids, nonalcoholic steatohepatitis, linseed oil, fish oil, alpha-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid, plasma lipid profile, triglycerides, dietary supplementation, liver histopathology
- MeSH
- liver, humans, hypertriglyceridemia, fatty acids, omega-3, linseed oil, fish oils, biopsy, severity of illness index, double-blind method, reproducibility of results, patient compliance, dietary supplements, middle aged, patient dropouts, hospitals, teaching, brazil, female, male, lost to follow-up, non-alcoholic fatty liver disease, biomarkers
10 autores
- Monize Aydar Nogueira🇧🇷Universidade de São Paulo
- Claudia Pinto Marques Souza de Oliveira🇧🇷Universidade de São Paulo
- Venâncio Avancini Ferreira Alves🇧🇷Universidade de São Paulo
- José Tadeu Stefano🇧🇷Universidade de São Paulo
- Livia Rodrigues🇧🇷Universidade de São Paulo
- Raquel Susana Torrinhas🇧🇷Universidade de São Paulo
- Bruno Cogliati🇧🇷Universidade de São Paulo
- Hermes Vieira Barbeiro🇧🇷Universidade de São Paulo
- Flair José Carrilho🇧🇷Universidade de São Paulo
- Dan Linetzky Waitzberg🇧🇷 · autor de correspondenciaUniversidade de São Paulo
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
& aims: Few clinical trials have addressed the potential benefits of omega-3 polyunsaturated fatty acids (PUFAs) on non-alcoholic steatohepatitis (NASH). We evaluated the effects of supplementation with omega-3 PUFAs from flaxseed and fish oils in patients with biopsy-proven NASH.
Methods
Patients received three capsules daily, each containing 0.315 g of omega-3 PUFAs (64% alpha-linolenic [ALA], 16% eicosapentaenoic [EPA], and 21% docosahexaenoic [DHA] acids; n-3 group, n = 27) or mineral oil (placebo group, n = 23). Liver biopsies were evaluated histopathologically by the NASH activity score (NAS). Plasma levels of omega-3 PUFAs were assessed as a marker of intake at baseline and after 6 months of treatment. Secondary endpoints included changes in plasma biochemical markers of lipid metabolism, inflammation, and liver function at baseline and after 3 and 6 months of treatment.
Results
At baseline, NAS was comparable between the groups (p = 0.98). After intervention with omega-3 PUFAs, plasma ALA and EPA levels increased (p ≤ 0.05). However in the placebo group, we also observed increased EPA and DHA (p ≤ 0.05), suggesting an off-protocol intake of PUFAs. NAS improvement/stabilization was correlated with increased ALA in the n-3 group (p = 0.02) and with increased EPA (p = 0.04) and DHA (p = 0.05) in the placebo group. Triglycerides were reduced after 3 months in the n-3 group compared to baseline (p = 0.01).
Conclusions
In NASH patients, the supplementation of omega-3 PUFA from flaxseed and fish oils significantly impacts on plasma lipid profile of patients with NASH. Plasma increase of these PUFAs was associated with better liver histology. (ID 01992809).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.